Approved by the Board on: 30 March 2021
The Board acknowledges its previous decision establishing the Global Fund COVID-19 Response Mechanism (C19RM) and agrees that the COVID-19 pandemic continues to have a devastating impact on global health systems, jeopardizing the fight against HIV, tuberculosis, and malaria and progress towards 2030 goals for the three diseases. Recognizing the acute needs at country-level, and the threat of diversion of resources towards COVID-19, the Board agrees that additional funding to support country responses to COVID-19 is necessary to safeguard the USD 14 billion raised through the 6th replenishment for HIV, tuberculosis, and malaria (HTM) programs. The Board further acknowledges that certain public donors wish to make significant additional pledges to the Global Fund to provide further support for country responses to COVID-19 and that this decision does not preclude further discussion and Board decisions within the Strategy development process on the future role and scope of Global Fund support for pandemic preparedness and response.
The Board agrees that C19RM should leverage existing Global Fund processes, controls, and frameworks, while acknowledging that modifications may be necessary to ensure the level of speed and agility necessary for an emergency response. The Board further agrees on the need for greater transparency on the operationalization and implementation of C19RM, to facilitate and ensure an appropriate degree of oversight from, and accountability to, the Board.
The Board therefore approves the following:
2. Use of funding:
4. Funding requests:
5. C19RM Funding Request Review and Approval:
6. Reporting, Monitoring and Evaluation:
7. Centrally Managed Investments
8. Management and Operating costs
9. Additional changes:
10. Limited exceptions to Quality Assurance Policies:
Incremental management and operating costs directly attributable to the proposed extension of C19RM will be covered from any additional funds made available for C19RM, pursuant to paragraph 8.a above. Such costs will not exceed 3% of any C19RM funding.